REAPPRAISING THE USE OF SYSTEMIC IVERMECTIN IN YOUNG INFANTS: EVIDENCE FROM CLINICAL PRACTICE

Authors

DOI:

https://doi.org/10.29176/30284163.2219

Keywords:

Ivermectin, Safety, Scabies, Young infants

Abstract

Scabies is a parasitic disease with major public health impact, and its management in young infants remains challenging. Historically, oral ivermectin in children <15 kg has been restricted due to a theoretical risk of neurotoxicity. However, this threshold is based on operational and precautionary criteria rather than established pathophysiological evidence. We report the case of a six-month-old infant with extensive scabies, successfully treated with oral ivermectin, achieving complete remission without adverse effects. This case supports its safety and efficacy, aligning with the paradigm shift toward extending its use in infants in selected clinical scenarios.

Author Biographies

María Angélica Macias Eslava, Universidad de Santiago de Chile

Facultad de Ciencias Médicas, Universidad de Santiago. Escuela de Medicina, Universidad de O'Higgins, Rancagua, Chile

Javiera Labbé-San Martín, University of O'Higgins

Escuela de Medicina, Universidad de O'Higgins, Rancagua, Chile.

Bárbara Vejar Núñez, University of O'Higgins

Escuela de Medicina, Universidad de O'Higgins, Rancagua, Chile

Maríajosé Gallardo Bejar, University of O'Higgins

Escuela de Medicina, Universidad de O'Higgins, Rancagua, Chile

Diego Marcelo Aragon Caqueo, Universidad de Santiago de Chile

Facultad de Ciencias Médicas, Universidad de Santiago, Santiago, Chile.

References

1) World Health Organization. Scabies. Geneva: World Health Organization; 2023. Disponible en: https://www.who.int/news-room/fact-sheets/detail/scabies. [Consultado el 11 de Agosto, 2025]

2) World Health Organization. Neglected tropical diseases. Geneva: World Health Organization; 2017. Disponible en: https://www.who.int/health-topics/neglected-tropical-diseases#tab=tab_1 [Consultado el 11 de Agosto, 2025]

3) World Health Organization. Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030. Geneva: World Health Organization; 2020. Disponible en: https://iris.who.int/bitstream/handle/10665/355448/9789240051423-eng.pdf?sequence=1. [Consultado el 11 de Agosto, 2025].

4) El-Moamly AA. Scabies as a part of the World Health Organization roadmap for neglected tropical diseases 2021-2030: what we know and what we need to do for global control. Trop Med Health. 2021;49(1):64. doi:10.1186/s41182-021-00348-6.

5) Arlian LG, Morgan MS. A review of Sarcoptes scabiei: past, present and future. Parasit Vectors. 2017;10(1):297. doi:10.1186/s13071-017-2234-1.

6) Enbiale W, Ayalew A. Investigation of a Scabies Outbreak in Drought-Affected Areas in Ethiopia. Trop Med Infect Dis. 2018;3(4):114. Published 2018 Oct 29. doi:10.3390/tropicalmed3040114

7) Karimkhani C, Colombara DV, Drucker AM, et al. The global burden of scabies: a cross-sectional analysis from the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;17(12):1247-1254. doi:10.1016/S1473-3099(17)30483-8

8) Burkhart CN, Burkhart CG. Before using ivermectin therapy for scabies. Pediatr Dermatol. 1999;16(6):478-480. doi:10.1046/j.1525-1470.1999.00124.x

9) Jittamala P, Monteiro W, Smit MR, et al. A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication?. PLoS Negl Trop Dis. 2021;15(3):e0009144.

10) Edwards G. Ivermectin: does P-glycoprotein play a role in neurotoxicity? Filaria Journal. 2003;2(Suppl 1):S8. 10.1186/1475-2883-2-S1-S.

11) Trailovic SM, Nedeljkovic JT. Central and peripheral neurotoxic effects of ivermectin in rats. J Vet Med Sci. 2011;73(5):591-599. doi:10.1292/jvms.10-0424.

12) Virgintino D, Errede M, Robertson D, Capobianco C, Girolamo F, Vimercati A, et al. Immunolocalization of tight junction proteins in the adult and developing human brain. Histochemistry and cell biology. 2004;122(1):51–9. 10.1007/s00418-004-0665-1.

13) Salavastru CM, Chosidow O, Boffa MJ, Janier M, Tiplica GS. European guideline for the management of scabies. J Eur Acad Dermatol Venereol. 2017;31(8):1248-1253. doi:10.1111/jdv.14351.

14) Uzun S, Durdu M, Yürekli A, et al. Clinical practice guidelines for the diagnosis and treatment of scabies. Int J Dermatol. 2024;63(12):1642-1656. doi:10.1111/ijd.17327.

15) World Health Organization. WHO Model List of Essential Medicines for Children - 9th list, 2023. Geneva: World Health Organization; 2023. Disponible en: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.03.[Consultado el 21 de Agosto, 2025].

16) Levy M, Martin L, Bursztejn AC, et al. Ivermectin safety in infants and children under 15 kg treated for scabies: a multicentric observational study. Br J Dermatol. 2020;182(4):1003-1006. doi:10.1111/bjd.18369.

17) Morand A, Weill A, Miquel J, et al. Management of scabies in children under 15 kg and pregnant or breastfeeding women: recommendations supported by the Centre of Evidence of the French Society of Dermatology. Br J Dermatol. 2024;191(6):1014-1016. doi:10.1093/bjd/ljae288.

18) Thadanipon K, Anothaisintawee T, Rattanasiri S, Thakkinstian A, Attia J. Efficacy and safety of antiscabietic agents: A systematic review and network meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2019;80(5):1435-1444. doi:10.1016/j.jaad.2019.01.004.

19) Colebunders R, Wafula ST, Hotterbeekx A, Siewe-Fodjo JN. Ivermectin use in children below 15 kg: potential benefits for onchocerciasis and scabies elimination programmes. Br J Dermatol. 2020;182(4):1064. doi:10.1111/bjd.18685

How to Cite

1.
Macias Eslava MA, Labbé-San Martín J, Vejar Núñez B, Gallardo Bejar M, Aragon Caqueo DM. REAPPRAISING THE USE OF SYSTEMIC IVERMECTIN IN YOUNG INFANTS: EVIDENCE FROM CLINICAL PRACTICE. Rev. Hispano-Am. Dermatol. Pediátr. [Internet]. 2026 Mar. 12 [cited 2026 Nov. 21];3(1). Available from: https://revista.asocolderma.org.co/index.php/dermaped/article/view/2219

Downloads

Download data is not yet available.

Published

2026-03-12

How to Cite

1.
Macias Eslava MA, Labbé-San Martín J, Vejar Núñez B, Gallardo Bejar M, Aragon Caqueo DM. REAPPRAISING THE USE OF SYSTEMIC IVERMECTIN IN YOUNG INFANTS: EVIDENCE FROM CLINICAL PRACTICE. Rev. Hispano-Am. Dermatol. Pediátr. [Internet]. 2026 Mar. 12 [cited 2026 Nov. 21];3(1). Available from: https://revista.asocolderma.org.co/index.php/dermaped/article/view/2219

Issue

Section

Case report
Scan to share
QR code to open and share this publication